Sjors M. Kas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sjors M. Kas has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anne Paulien Drenth
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Bjørn Siteur
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Catrin Lutz
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Chi-Chuan Lin
School of Molecular and Cellular Biology, Centre for Plant Sciences and Astbury Centre for Structural Molecular Biology University of Leeds Leeds LS2 9JT UK
15 shared publications - Daniel Zingg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Eline van der Burg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the in vitro and in vivo Fgfr2-E18 C-tail motif analyses.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the in vitro and in vivo Fgfr2-E18 C-tail motif analyses.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with Fgfr2-E18 C-tail motif variants
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with Fgfr2-E18 C-tail motif variants